• 1. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 2. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Coumarans Coumarans
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Coumarans

Introduction to 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone (CAS No. 151427-19-9)

2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone, identified by its Chemical Abstracts Service Number (CAS No.) 151427-19-9, is a significant compound in the realm of pharmaceutical chemistry and organic synthesis. This molecule, featuring a brominated aromatic ring and a benzofuran moiety, has garnered attention due to its versatile structural framework and potential applications in drug discovery and material science. The presence of both bromine and oxygen-containing heterocycles makes it a valuable intermediate for constructing more complex molecules, particularly in the development of bioactive compounds.

The structure of 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone encompasses a ketone group (C=O) linked to a brominated ethyl side chain, with the benzofuran ring contributing additional functional diversity. This arrangement allows for various chemical modifications, enabling chemists to explore diverse synthetic pathways. The benzofuran scaffold, known for its stability and biological relevance, is frequently employed in medicinal chemistry due to its ability to interact with biological targets. The bromine substituent further enhances reactivity, making it a convenient handle for further functionalization via cross-coupling reactions such as Suzuki or Buchwald-Hartwig couplings.

In recent years, there has been growing interest in benzofuran derivatives as pharmacophores due to their demonstrated efficacy in modulating various biological processes. For instance, studies have highlighted the potential of benzofuran-based compounds in inhibiting enzymes associated with inflammatory diseases and cancer metabolism. The brominated derivatives, in particular, have shown enhanced binding affinity and metabolic stability, attributes that are critical for drug candidates. The compound CAS No. 151427-19-9 fits well within this category, offering a scaffold that can be modified to target specific therapeutic areas.

One of the most compelling aspects of 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone is its utility as a building block in the synthesis of more complex molecules. Researchers have leveraged this compound to develop novel analogs with improved pharmacokinetic properties. For example, modifications at the bromine or benzofuran positions can lead to derivatives with enhanced solubility or selectivity for certain biological receptors. Such structural diversification is essential for optimizing drug candidates throughout the development pipeline.

The pharmaceutical industry has been particularly keen on exploring ketone-containing heterocycles due to their role as key pharmacophores in numerous therapeutic agents. The ketone group in 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone serves as a versatile handle for further chemical transformations. It can be reduced to an alcohol or alkene, oxidized to an ester or acid derivative, or participate in enamine formation—each pathway opening new avenues for molecular design. This flexibility underscores the compound’s importance as an intermediate in synthetic chemistry.

Recent advancements in combinatorial chemistry and high-throughput screening have further highlighted the significance of such versatile intermediates like CAS No. 151427-19-9. These techniques allow researchers to rapidly generate libraries of derivatives and screen them for biological activity. The benzofuran-ketone-bromine framework provides an excellent starting point for such explorations because it balances structural complexity with synthetic accessibility.

The biological activity of 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethanone and its derivatives remains an active area of investigation. Preliminary studies suggest that certain modifications at the benzofuran ring can modulate enzyme inhibition profiles relevant to neurological disorders and metabolic diseases. For instance, analogs with electron-withdrawing groups at specific positions have shown promise in preclinical models as inhibitors of kinases or other therapeutic targets. Such findings underscore the need for continued exploration of this chemical space.

From a synthetic chemistry perspective, one notable feature of CAS No. 151427-19-9 is its amenability to asymmetric synthesis if required. The presence of chiral centers adjacent to functional groups allows for the construction of enantiomerically pure derivatives using catalytic methods such as asymmetric hydrogenation or chiral auxiliaries. This capability is crucial for developing drugs where stereochemistry dictates efficacy and safety.

The broader significance of this compound lies in its alignment with emerging trends in drug discovery—namely the emphasis on structure-based design and rational molecular optimization. By providing a robust scaffold like that found in 2-Bromo-1-(2,3-dihydro-1-benzofuran-5-yilethanone), researchers can systematically probe biological activity while maintaining synthetic tractability throughout multiple rounds of modification.

In conclusion,CAS No. 151427-19-9 represents a valuable asset for pharmaceutical chemists seeking novel molecular architectures with potential therapeutic applications across multiple disease areas including cancer metabolism disorders, inflammatory conditions,and neurological diseases among others.. Its unique combination of functional groups—ketone, bromine,and benzofuran—makes it an ideal candidate for further exploration through both traditional organic synthesis techniques and modern high-throughput methodologies.. As research progresses,this compound is likely to play an increasingly important rolein shaping next-generation drug candidates..

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)